ArticleNeuropsychiatric disease and treatment2026
Long-Term Effectiveness and Safety of LCIG in Romania. 3-year Results from a Prospective, Observational Study (DUOGLOBE).
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02611713 (DUOdopa/Duopa in Patients With Advanced Parkinson's Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Levodopa-carbidopa intestinal gel (LCIG) is an established treatment for patients with advanced Parkinson's disease (APD). Improvement of motor and non-motor symptoms, as well as the quality of life has been proven in clinical trials. Prospective long-term data in routine clinical practice are limited. Objective: To assess the effectiveness and safety of LCIG over a 36-month prospective follow-up in Romania, as part of the DUOGLOBE international non-interventional study. Methods: DUOGLOBE (DUOdopa/Duopa in Patients with APD - a GLobal OBservational Study Evaluating Long-Term Effectiveness; NCT02611713) was a long-term observational study in patients with APD receiving LCIG as part of their treatment strategy in routine clinical care. Prospective data up to 36 months from LCIG initiation were collected in the study. The primary objective assessed the change in OFF time from baseline to 36 months. Results: Of the total number of 195 patients enrolled worldwide, 51 patients were included in 6 movement disorder centers in Romania. In these patients, LCIG was initiated after a median disease duration of 8.1 years (1.6-19.7). The need for concomitant anti-PD medication decreased within one month after LCIG initiation and remained stable for up to 36 months. The OFF time was significantly reduced by LCIG treatment at all timepoints vs baseline (p<0.001) (mean change [standard deviation, SD] at final visit: -3.4 ± 2.8 hours). Improvement of dyskinesia was recorded at 36 months (mean change [SD] of the Unified Dyskinesia Rating Scale at final visit -9.0 [16.54], p=0.006). Improvements in non-motor symptoms and quality of life were consistent from Day 1 throughout the study. Safety was consistent with the well-established LCIG profile and with the global study results (serious adverse events [SAEs]): 49.0% of patients discontinued the therapy (27.5% due to SAEs). Conclusion: DUOGLOBE provides long-term data on routine practice in Romania and consistent LCIG benefits in patients with APD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.